Intravitreal Injectables Market By Indication (Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusions, Endophthalmitis, Others), By Drug Class (Anti-VEGF, Corticosteroids, Antibiotics, Antivirals, Antifungals) - Growth, Future Prospects, Competitive Analysis, 2018 - 2026
Industry Outlook
The Intravitreal injectables market will be showcasing stable growth at a compound annual growth rate (CAGR) of 4.8% during the forecast period from 2018 to 2026. According to the statistics provided by World Health Organization (WHO) approximately 1.3 billion people throughout the globe are suffering with some form of blindness caused majorly due to macular degeneration, diabetic retinopathy, ocular vein occlusions, endophthalmitis and retinitis. Intravitreal injections are being preferred over other treatment options for treating disease associated visual impairment.
"Rising prevalence of diabetes and increasing geriatric population drive macular degeneration market growth"
As per the research citing of the Lancet journal the global prevalence rate of any age related macular degeneration is 8.69% with a higher prevalence rate in the Caucasian population followed by mongoloids. The primary factors that increase the risk factor for occurrence of macular degeneration are increasing geriatric population, smoking, obesity, genetic, diabetes etc. Diabetic retinopathy is a secondary disease manifestation occurring in elderly people having previous history of diabetes. Endophthalmitis is growing at faster rate owing to rise in air and water pollution and eye trauma.
"Excellent biocompatibility and impressive pharmacodynamic properties drive the anti-VEGF drugs market"
Anti-VEGF is dominating the drug class segment for Intravitreal injections market. Since its commercialization in 2006 drugs such as bevacizumab (Avastin), ranibizumab (Lucentis) etc. are considered as the first line drug therapy in patients suffering with neovascular age related macular degeneration and ocular vein occlusion. Its inherent features such as excellent biocompatibility and impressive pharmacodynamic properties has led to its increased popularity among ophthalmologist worldwide. Corticosteroids are used as an adjuvant drug therapy in alleviating inflammation caused due to eye infections. Antifungal drugs and antibiotics together are prescribed in eye infections such as endophthalmitis and retinitis.
"Rising prevalence of eye disorders and affordable reimbursement scenario drive the Intravitreal injectables market growth"
In the present situation North America is accountable for 37% market share in the regional segment for Intravitreal injectables market. As per the statistics provided by the Center for Disease Control and Prevention (CDC), approximately 3.3 million Americans aged 40 years and older are blind or suffering with low vision. Rising prevalence of eye disorders and affordable reimbursement scenario drive the market growth in North America. Europe represents 26% share on account of the presence of thriving healthcare infrastructure and domicile of key players such as Novartis AG, Allergan, Inc., Alimera Sciences, F.Hoffman-La Roche Ltd. etc. propel the market growth in Europe. Asia Pacific is holding 20% market share and is keen to capture the regional market in the near future on account of supportive regulatory environment provided by healthcare agencies and developing ophthalmic research centers providing optimum eye care.
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Pharmaceutical giants competing to maintain stronghold in intravitreal injectables market are Allergan, Inc., Genetech, Inc., Alimera Sciences, Bristol-Myers Squibb Company, Eyetech, Inc., F.Hoffman-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., ThromboGenics, Inc. and Valeant Pharmaceuticals International, Inc.
Key questions answered in this report
- Which pharmaceutical companies are manufacturing Intravitreal injectables for treating eye disorders?
- What are the strength, weakness and opportunities associated with Intravitreal injectables market growth?
- What is the pathophysiology associated with diseases such as macular degeneration, diabetic retinopathy and endophthalmitis?
- Which treatment regimen is considered for the treatment of macular degeneration?
- What is the pharmacodynamic effect of Anti-VEGF drugs in treating eye disorders?
- What will be the market assessment for Intravitreal injectables in Asia Pacific regional market?
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global II Market Portraiture
2.2. Global II Market, by Indication, 2017 (US$ Mn)
2.3. Global II Market, by Drug Class, 2017 (US$ Mn)
2.4. Global II Market, by Geography, 2017 (US$ Mn)
Chapter 3. Intravitreal Injectables (II) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global II Market, by Key Players, 2017
Chapter 4. Global Intravitreal Injectables (II) Market, by Indication
4.1. Overview
4.2. Macular Degeneration
4.3. Diabetic Retinopathy
4.4. Retinal Vein Occlusions
4.5. Endophthalmitis
4.6. Others
Chapter 5. Global Intravitreal Injectables (II) Market, by Drug Class
5.1. Overview
5.2. Anti-VEGF
5.3. Corticosteroids
5.4. Antibiotics
5.5. Antivirals
5.6. Antifungals
Chapter 6. Global Intravitreal Injectables (II) Market, by Geography
6.1. Overview
6.2. North America II Market Analysis, 2016 – 2026
6.2.1. North America II Market, by Indication, 2016 – 2026 (US$ Mn)
6.2.2. North America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.2.3. North America II Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe II Market Analysis, 2016 – 2026
6.3.1. Europe II Market, by Indication, 2016 – 2026 (US$ Mn)
6.3.2. Europe II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.3.3. Europe II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific II Market Analysis, 2016 – 2026
6.4.1. Asia Pacific II Market, by Indication, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.4.3. Asia Pacific II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America II Market Analysis, 2016 – 2026
6.5.1. Latin America II Market, by Indication, 2016 – 2026 (US$ Mn)
6.5.2. Latin America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.5.3. Latin America II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa II Market Analysis, 2016 – 2026
6.6.1. MEA II Market, by Indication, 2016 – 2026 (US$ Mn)
6.6.2. MEA II Market, by Drug Class, 2016 – 2026 (US$ Mn)
6.6.3. MEA II Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA
Chapter 7. Company Profiles
7.1. Allergan, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Alimera Sciences
7.3. Bristol-Myers Squibb Company
7.4. Eyetech, Inc.
7.5. F. Hoffmann-La Roche Ltd
7.6. Genentech, Inc.
7.7. Novartis AG
7.8. Regeneron Pharmaceuticals, Inc.
7.9. ThromboGenics, Inc.
7.10. Valeant Pharmaceuticals International, Inc.
* II - Intravitreal Injectables
TABLE 1 : Global Intravitreal Injectables (II) Market Portraiture
TABLE 2 : Global II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 3 : Global II Market , by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 4 : Global II Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 5 : North America II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 6 : North America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 : North America II Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 : Europe II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 9 : Europe II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 10 : Europe II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 11 : Asia Pacific II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 12 : Asia Pacific II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 13 : Asia Pacific II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 : Latin America II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 15 : Latin America II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 16 : Latin America II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 17 : Middle East and Africa II Market, by Indication, 2016 – 2026 (US$ Mn)
TABLE 18 : Middle East and Africa II Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 19 : Middle East and Africa II Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 20 : Allergan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 : Alimera Sciences: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 : Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 : Eyetech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 : F.Hoffman-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 : Genetech, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 : Regeneron Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 : ThromboGenics, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 : Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
FIG. 1 : Intravitreal Injectables (II) Market: Research Methodology
FIG. 2 : II: Market Segmentation
FIG. 3 : Global II Market, by Indication, 2017 (US$ Mn)
FIG. 4 : Global II Market, by Drug Class, 2017 (US$ Mn)
FIG. 5 : Global II Market, by Geography, 2017 (US$ Mn)
FIG. 6 : Attractive Investment Proposition: by Geography, 2017
FIG. 7 : Competitive Analysis: Global II Market, by Key Players, 2017
FIG. 8 : Global Macular Degeneration Market for II, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Diabetic Retinopathy Market for II, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Retinal Vein Occlusions Market for II, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Endophthalmitis Market for II, 2016 – 2026 (US$ Mn)
FIG. 12 : Global Other Indications Market for II, 2016 – 2026 (US$ Mn)
FIG. 13 : Global Anti-VEGF Market for II, 2016 – 2026 (US$ Mn)
FIG. 14 : Global Corticosteroids Market for II, 2016 – 2026 (US$ Mn)
FIG. 15 : Global Antibiotics Market for II, 2016 – 2026 (US$ Mn)
FIG. 16 : Global Antivirals Market for II, 2016 – 2026 (US$ Mn)
FIG. 17 : Global Antifungals Market for II, 2016 – 2026 (US$ Mn)
FIG. 18 : U.S. II Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Canada II Market, 2016 – 2026 (US$ Mn)
FIG. 20 : U.K. II Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Germany II Market, 2016 – 2026 (US$ Mn)
FIG. 22 : Rest of Europe II Market, 2016 – 2026 (US$ Mn)
FIG. 23 : China II Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Japan II Market, 2016 – 2026 (US$ Mn)
FIG. 25 : Rest of Asia Pacific II Market, 2016 – 2026 (US$ Mn)
FIG. 26 : Brazil II Market, 2016 – 2026 (US$ Mn)
FIG. 27 : Mexico II Market, 2016 – 2026 (US$ Mn)
FIG. 28 : Rest of Latin America II Market, 2016 – 2026 (US$ Mn)
FIG. 29 : GCC II Market, 2016 – 2026 (US$ Mn)
FIG. 30 : Rest of MEA II Market, 2016 – 2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)